Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan

Abstract

Definitive risk factors for the development of adult T-cell leukemia (ATL) among asymptomatic human T-cell leukemia vi-

Plasma Soluble CD30 as a Possible Marker of Adult T-cell Leukemia in HTLV-1 Carriers: a Nested Case-Control Study

“…Anonymized demographical data, laboratory data, clinical data, and stored plasma samples from HTLV-1 carriers were obtained from a nationwide cohort study of HTLV-1 carriers in Japan [Joint Study on Predisposing Factors of ATL Development (JSPFAD)] (Iwanaga et al, 2010), after approval by the JSPFAD committee (approved number 2012-5) and by the Institutional Review Board of the National Hospital Organization Kumamoto Medical Center (No. 391 on May 21, 2012).…”

“…391 on May 21, 2012). Details of the JSPFAD have been previously reported (Iwanaga et al, 2010). In brief, the project was established in August 2002, consisting of 14 university hospitals and 27 educational hospitals located in a wide range of areas in Japan for the purpose of investigating risk factors for the development of ATL by prospectively following a large number of participants of asymptomatic HTLV-1 carriers.…”

“…In the database of the JSPFAD during 2002 to 2008, 14 asymptomatic HTLV-1 carriers progressed to overt ATL (two acute, two lymphoma, and 10 smoldering types) (Iwanaga et al, 2010). Blood samples pre-and post-ATL development were available in 11 of 14 cases.…”

“…% of PBMCs) (Iwanaga et al, 2010). Detailed methods for the measurement of HTLV-1 proviral load were described in a previous JSPFAD report (Iwanaga et al, 2010).…”

“…% of PBMCs) (Iwanaga et al, 2010). Detailed methods for the measurement of HTLV-1 proviral load were described in a previous JSPFAD report (Iwanaga et al, 2010). In this study, plasma sCD30 concentration was measured, after plasma samples were provided by the biomaterial bank of the JSPFAD, by using the Human sCD30 Platinum ELISA kit (eBioscience, Vienna, Austria) according to the manufacture's protocol at the Research Laboratories of Kyowa Medex Co., Ltd., Shizuoka, Japan.…”